+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
R

Actively Recruiting

Researchers are evaluating radiation treatments for women with small, node-negative invasive breast cancer measuring 3 cm or less. This trial compares partial breast irradiation PBI to whole breast irradiation WBI, both given once daily over about one week after breast-conserving surgery. The main goal is to see if PBI is not worse than WBI for preventing local cancer recurrence and if it improves cosmetic outcomes, as judged by patients, three years after treatment. Participants are randomly assigned to receive either PBI or WBI. Both groups receive a total radiation dose of 26 Gy split into five daily treatments over 5 to 7 days, with a possible extension to 8 days due to scheduling. The WBI targets the entire breast, while PBI focuses radiation on the tumor bed plus a margin of normal tissue. Patients are not informed which treatment they receive to avoid bias in assessing cosmetic results. Key factors such as tumor size, estrogen receptor status, and treatment center are used for group assignment. During the study, participants will be monitored annually for five years to assess local recurrence, distant disease-free survival, overall survival, and radiation side effects. Cosmetic outcomes will be evaluated by both patients and clinical staff at 3 and 5 years. Quality of life will also be measured at multiple time points. The study lasts several years, with primary outcomes assessed at three years and continued follow-up through at least five years post-treatment.

Age: 50Years - 120YearsFEMALEPhase 3
31 locations
E

Actively Recruiting

Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.

Age: 18Years +All GendersPhase 3
242 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
C

Actively Recruiting

Researchers are investigating new treatment options for people with proficient mismatch repair pMMR endometrial cancer that is advanced or has returned after surgery. This cancer begins in the lining of the uterus and has either spread locally or to other parts of the body, making surgery not an option. The study aims to compare combining sacituzumab tirumotecan sac-TMT with pembrolizumab against pembrolizumab alone to see if it helps patients live longer without the cancer worsening. Participants first receive an Induction Phase treatment of six cycles every three weeks involving pembrolizumab plus either carboplatin or cisplatin combined with paclitaxel or docetaxel. If the cancer does not progress, they move to a Maintenance Treatment Phase where they are randomly assigned to receive pembrolizumab with sac-TMT or pembrolizumab alone. If the cancer progresses, participants may enter a Subsequent Treatment Phase with random assignment to pembrolizumab plus sac-TMT or sac-TMT alone. Treatments are given by intravenous infusion following specific dosing schedules over several months. Throughout the study, participants undergo regular assessments including scans to evaluate cancer progression, monitoring for side effects, and quality of life questionnaires. Researchers will measure progression-free survival and overall survival up to approximately 44 and 54 months respectively. The study also tracks adverse events and changes in physical and role functioning. The total participation can last up to several years with careful monitoring to assess treatment outcomes and safety.

Age: 18Years +FEMALEPhase 3
268 locations
S

Actively Recruiting

Researchers are evaluating a new treatment combination for adults with advanced small cell lung cancer SCLC. The study compares a medicine called obrixtamig combined with standard treatment atezolizumab, carboplatin, and etoposide against the standard treatment alone. Obrixtamig is an antibody-like molecule designed to help the immune system fight cancer. The study also tests a new medical device to measure levels of a tumor marker called DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus the standard treatment, while the other group receives only the standard treatment. All drugs are given through infusions into a vein. Participants in the obrixtamig group stay overnight at the study site after their first two obrixtamig treatments. The study lasts for up to three years, during which participants visit the study site regularly. Throughout the study, doctors monitor tumor size to compare results between groups. They also check participants overall health and note any side effects. Researchers measure outcomes such as overall survival, progression-free survival, symptom changes, treatment responses, and any treatment-related side effects. Participants are closely observed for up to 36 months to evaluate these effects and safety.

Age: 18Years +All GendersPhase 3
243 locations
A

Actively Recruiting

This research aims to understand whether patients involved in clinical trials are willing to provide information about social, economic, and environmental factors that affect their health experiences and access to care. These factors, known as social determinants of health, include income, education, employment, housing, social supports, and experiences with discrimination or stress. The study is sponsored by the Canadian Cancer Trials Group and focuses on participants related to cancer clinical trials. Participants will be asked to complete a standardized Social Determinants of Health SDoH Questionnaire in English or French, which collects detailed sociodemographic data. This questionnaire covers the conditions and places where participants live, learn, work, and play, as well as their feelings about answering such questions. The study involves both participants being screened for CCTG trials and those already enrolled and under follow-up in ongoing trials. Participation takes about 10 minutes or less. Researchers will evaluate how feasible it is to collect these comprehensive sociodemographic data and how acceptable the questionnaire is to participants over a 12-month period. The main outcome is the completion and willingness to provide this information. This observational study does not include any treatment, and participants usual care continues as normal throughout the study period.

Age: 18Years +All Genders
15 locations
C

Actively Recruiting

Researchers are evaluating treatment strategies for transplant-ineligible older adults with newly diagnosed multiple myeloma. The study compares continuous use of anti-CD38 antibodies daratumumab or isatuximab alongside lenalidomide and dexamethasone against a fixed duration approach where these antibodies are stopped after about a year and a half. The goal is to determine if a shorter antibody treatment works as well as continuous therapy. Participants will be randomly assigned to one of two groups. One group will continue standard care with ongoing daratumumab or isatuximab combined with lenalidomide and dexamethasone. The other group will stop the antibody injections after completing 18-20 cycles but continue the other medications indefinitely as long as they benefit. The study includes two treatment arms one with lenalidomide and dexamethasone alone, and the other with those drugs plus daratumumab or isatuximab. During the trial, participants will undergo regular assessments including measurements of disease progression, survival, response rates, side effects, quality of life, and economic factors over a period of approximately 9 years. Researchers will monitor the safety and effectiveness of the treatments and gather data through questionnaires and clinical evaluations. Participants will remain on treatment as long as they continue to benefit and will be followed closely throughout the study duration.

Age: 18Years +All GendersPhase 3
31 locations

1-10 of 14

1